A digital therapeutic for management of psychosocial aspects of psoriasis: A pre‐post proof of concept study

Fortune, Dónal G.; Ravnkilde, V.; Ryan, Sheila; Ramsay, B.; Clough, S.; Richards, Helen L.

doi:10.1002/ski2.103

Cited by 10 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mobile phone-based disease monitoring application for patients with psoriasis in combination with a patient educational programme was developed and applied 17. Allay mHealth intervention, a 12-week bespoke digital therapeutic intervention for patients with psoriasis, is designed as an adjunct to medical management of the condition, which may help patients improve resilience, mood and beliefs on their condition and enhance their QOL 66. Using a participatory design, the mHealth app supported the self-management of patients with psoriasis 65 67.…”

Section: Resultsmentioning

confidence: 99%

“…17 Allay mHealth intervention, a 12-week bespoke digital therapeutic intervention for patients with psoriasis, is designed as an adjunct to medical management of the condition, which may help patients improve resilience, mood and beliefs on their condition and enhance their QOL. 66 Using a participatory design, the mHealth app supported the selfmanagement of patients with psoriasis. 65 67 The Electronic Targeted Intervention (eTIPs study) for patients with psoriasis was established.…”

Section: Different Nationwide Hcms Of Patients With Psoriasismentioning

confidence: 99%

See 1 more Smart Citation

Non-pharmacological interventions for patients with psoriasis: a scoping review

Zhang,

Lin,

Feng

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesHealthcare ultimately aims to eradicate diseases and restore normality to people’s lives. However, until this is achieved for every person, there is a need to support and assist patients with psoriasis using non-pharmacological interventions. These ‘adjuvant’ approaches have received little attention, whereas dermatologists and researchers strive for better pharmacological therapy. Here, we aimed to perform a scoping review to identify and catalogue non-pharmacological interventions for patients with psoriasis.DesignA scoping review.SettingAll healthcare settings.Search strategyEMBASE, PubMed, CINAHL, PsycINFO and Scopus databases were searched from their inception to June 2022. Irrespective of the study type, the studies included non-pharmacological interventions for patients with psoriasis. This theme was extracted from the included articles. Two reviewers independently screened and analysed the data.ResultsFrom 1322 initial records, 71 studies were identified and analysed. Non-pharmacological interventions for patients with psoriasis include two levels: organisational and individual. The organisational non-pharmacological interventions included the nationwide healthcare model (PsPSP, ProvenCare, German PsoHealth and Psoriasis Network, IMPROVE model and PsoWell clinic), innovative teledermatology models (mHealth app, electronic Targeted Intervention for Psoriasis study and therapist-guided internet-based cognitive and behavioural treatments) and multidisciplinary interventions. The individual non-pharmacological interventions included educational interventions (therapeutic patient education, psychoeducational intervention and self-management education), psychosocial interventions (cognitive and behavioural treatments, self-help and peer-to-peer support programmes) and others (happify and motivational interviewing-based training).ConclusionsBased on previous literature, a nationwide healthcare model protocol was constructed for patients with psoriasis. This provided the direction for developing a new psoriasis healthcare model and a basis for summarising the non-pharmacological interventions for patients with psoriasis, which helps them adjust to changes in the skin disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Different Nationwide Hcms Of Patients With Psoriasismentioning

confidence: 99%

Non-pharmacological interventions for patients with psoriasis: a scoping review

Zhang,

Lin,

Feng

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Despite therapeutic efforts, psoriasis substantially impacts patient’s psychosocial well-being [ 30 ]. Embarrassment and stigmatization at work and in the community can lead to psychological morbidity [ 32 ]. Most patients in the present study mentioned facing humiliation and discrimination in the workplace and society because of their skin condition.…”

Section: Discussionmentioning

confidence: 99%

Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia

Affandi,

Thiruchelvam

2024

PLoS ONE

View full text Add to dashboard Cite

Background Psoriasis is a chronic erythematous inflammatory skin disorder. The major challenge with psoriasis is delayed diagnosis, resulting in delayed treatment initiation and reduced quality of life (QoL). Objective This patient perspective study aimed to explore the emotional and psychosocial burdens faced by patients with psoriasis in Malaysia and their attitudes toward current psoriasis treatment. Methods Adult patients with mild or moderate-to-severe plaque psoriasis, preferably with concomitant psoriatic arthritis, participated in a patient advisory board meeting along with a senior consultant dermatologist. Patients had to describe their initial symptoms, time of diagnosis, misdiagnosis, treatment initiation delays, treatment course, flare-ups, psychosocial impact, and QoL associated with psoriasis. Results The 11 participating patients had a mean age of 46 years with mean age of psoriasis diagnosis and an average year of suffering with psoriasis being 21.9 years and 24.5 years, respectively. The most common initial symptom of psoriasis was itching (62.5%), particularly of the scalp followed by itchiness and red patches on skin. Most patients (90%) reported initial misdiagnosis with other skin diseases by their primary care physicians (PCPs), which led to delayed treatment initiation. Most patients reported an emotional impact of psoriasis, including low self-esteem (18%), lack of confidence (27%), shock (18%), sadness (9%), and outrage (9%). Social discrimination/stigmatization in public places and at work (45%), and even from relatives (18%) was another reported challenge. However, 73% of patients were highly satisfied with the current treatment. Overall, the patients agreed that the lack of public awareness of psoriasis was responsible for the social stigma. Conclusions The evidence obtained from this qualitative study indicated that psoriasis has a significant emotional and psychological impact on the patients affecting their QoL. Lack of awareness of the disease among PCPs, patients, and the public is a major challenge leading to poor treatment outcomes.

show abstract

A digital therapeutic for management of psychosocial aspects of psoriasis: A pre‐post proof of concept study

Fortune

Ravnkilde

Ryan

et al. 2022

Skin Health and Disease

View full text Add to dashboard Cite

Background Despite the psychosocial challenges of living with psoriasis many patients may not be able to access appropriate services to manage these challenges. Mobile health interventions may be helpful as a means to support patients in managing the impact of their condition. Objective To conduct a preliminary examination of the feasibility and acceptability of a bespoke psoriasis‐specific digital therapeutic solution (hereafter termed Allay ), and to provide initial data on psychological changes pre‐post. Methods Phase one proof of concept pre‐post study. Eligible patients were provided with Allay on their smartphone and assessed at baseline and at 12 weeks on a range of indices of well‐being. Participants experiences on usability were collected by telephone interview at 4 weeks, 8 and 12 weeks. Results Out of 66 participants recruited, 59 persisted in using Allay after the familiarisation phase, and 34 participants completed the 12 weeks programme. Participants showed a statistically significant improvement between induction and the end of the 12 weeks programme on Quality of life, Resilience, Perceptions of ‘Overall impact’ of psoriasis, and ‘Emotional impact’. There was a significant change over the course of using Allay for symptoms of depression but not anxiety. While there was an interaction effect of changes in severity of psoriasis symptoms over the course of the study for dermatology‐specific measures, there was no interaction between such changes in psoriasis symptoms and changes in depression, resilience or beliefs in emotional impact. Conclusions Study results suggest that the use of Allay as an adjunct to medical management of psoriasis may help patients improve resilience, mood, beliefs about their condition and enhance their quality of life. Given that this is a phase one proof of concept study, and our rates of attrition further research is necessary to examine comparative effectiveness and stability of these findings.

show abstract

A digital therapeutic for management of psychosocial aspects of psoriasis: A pre‐post proof of concept study

Cited by 10 publications

References 46 publications

Non-pharmacological interventions for patients with psoriasis: a scoping review

Non-pharmacological interventions for patients with psoriasis: a scoping review

Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia

A digital therapeutic for management of psychosocial aspects of psoriasis: A pre‐post proof of concept study

Contact Info

Product

Resources

About